.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA06_Ifosfamide.Ifosfamide .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA06_Ifosfamide.Ifosfamide| name: | Ifosfamide |
| ATC code: | L01AA06 | route: | intravenous |
| n-compartments | 2 |
Ifosfamide is an alkylating agent of the oxazaphosphorine group, used primarily as a chemotherapeutic agent for the treatment of various cancers including testicular cancer, sarcomas, and lymphomas. It is an FDA-approved cytotoxic drug commonly administered in combination with other chemotherapeutics.
Pharmacokinetic parameters reported in adult cancer patients (various types, both sexes), administered as intravenous infusion.
Reif, S, et al., & Jaehde, U (2002). Population pharmacokinetics of etoposide. International journal of clinical pharmacology and therapeutics 40(12) 578–579. DOI:10.5414/cpp40578 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12503821
Kerbusch, T, et al., & Beijnen, JH (2001). Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients. Cancer chemotherapy and pharmacology 48(1) 53–61. DOI:10.1007/s002800100277 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11488525
Kerbusch, T, et al., & Beijnen, JH (2001). Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. European journal of clinical pharmacology 57(6-7) 467–477. DOI:10.1007/s002280100322 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11699611